Liposarcoma Treatments

Find Liposarcoma Treatments

Brand Name

Halaven

Generic Name

Eribulin

View Brand Information

FDA approval date: November 15, 2010

Classification: Microtubule Inhibitor

Form: Injection, Solution

What is Halaven (Eribulin)?

HALAVEN is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer

Who is this study for: Patients with Metastatic Breast Cancer, Chemotherapy-induced Alopecia

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug, Device

Study Drugs: Eribulin, Sacituzumab Govitecan, Trastuzumab Deruxtecan

Study Phase: Phase 2

Summary: This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System

A Prospective, Randomized Controlled Phase II Trial Investigating the Optimal Timing of Antibody Drug Conjugates in Advanced HER2-Negative Breast Cancer Patients

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug

Study Phase: Phase 2

Objective: To compare the difference in PFS2 (Time from randomization to disease progression after second therapy) between antibody-drug conjugate (ADC) followed by chemotherapy versus chemotherapy followed by ADC in the treatment of advanced HER2-negative breast cancer. Secondary

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Who is this study for: Adult patients with metastatic or inoperable locally advanced triple negative breast cancer

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Drugs: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan

Study Phase: Phase 1/Phase 2

Summary: This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior s...

View All Clinical Trials

Related Latest Advances

A case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making.

Journal: Palliative & supportive care

Published: May 14, 2026

The Evolving Landscape of Systemic Therapy for Liposarcoma.

Journal: Cancers

Published: April 21, 2026

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Journal: Anti-cancer drugs

Published: April 15, 2026

View All Latest Advances

Brand Information

Halaven (eribulin mesylate)

1DOSAGE FORMS AND STRENGTHS

Injection: 1 mg/2 mL (0.5 mg/mL) eribulin mesylate is a clear, colorless, sterile solution in a single-dose vial.

2CONTRAINDICATIONS

None.

3OVERDOSAGE

Overdosage of HALAVEN has been reported at approximately 4 times the recommended dose, which resulted in Grade 3 neutropenia lasting seven days and a Grade 3 hypersensitivity reaction lasting one day.

There is no known antidote for HALAVEN overdose.

4DESCRIPTION

HALAVEN contains eribulin mesylate, a microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge

a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesylate is 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt). It has a molecular weight of 826.0 (729.9 for free base). The empirical formula is C40H59NO11•CH4O3S. Eribulin mesylate has the following structural formula:

HALAVEN is a clear, colorless, sterile solution for intravenous administration. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution. Each mL of solution contains 0.5 mg of eribulin mesylate (equivalent to 0.44 mg eribulin) in dehydrated alcohol (5% v/v) and water for injection (95% v/v). Sodium hydroxide or hydrochloric acid may be used for pH adjustment.

5REFERENCES

1. OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

6HOW SUPPLIED/STORAGE AND HANDLING

NDC 62856-389-01

Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton.

Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86° F). Do not freeze or refrigerate. Store the vials in their original cartons.

HALAVEN injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹

7PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling

Neutropenia

Advise patients to contact their health care provider for a fever of 100.5°F or greater or other signs or symptoms of infection such as chills, cough, or burning or pain on urination

Peripheral Neuropathy

Advise patients to inform their healthcare providers of new or worsening numbness, tingling and pain in their extremities

Embryo-Fetal Toxicity

Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy
Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks after the final dose
Advise males with female partners of reproductive potential to use effective contraception

Lactation

Advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose

Distributed by: